SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Pomalyst/Imnovid

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved / marketed (originally approved Feb 2013); still used as the comparator/backbone arm in other sponsors' Phase 3
Time to market
Already marketed, FDA approval catalyst recorded 2013-02-08; generic pomalidomide (Camber Pharmaceuticals, ANDA210236) already has U.S. labeling, so the brand's exclusivity is gone.
Why 2/10
No hard, dated catalyst exists for Pomalyst itself in the next ~12 months (it was approved on 2013-02-08 and faces generic competition), and it is a small, declining slice of a mega-cap's portfolio, so it cannot drive BMY's share price; score 2 (approved, minor program within a large pipeline, nothing scheduled).
Actionable Insight NEUTRAL

Do not trade BMY on Pomalyst, there is no pending approval, readout, or label decision for this drug. Watch BMS quarterly filings (latest 10-Q filed 2026-07-30) for Pomalyst/Imnovid sales erosion vs. generics, and note that the real near-term myeloma catalyst for the ticker is a DIFFERENT molecule: BMY's next-gen IMiD iberdomide has a PDUFA of 2026-08-17 per SecBot event data. An AbbVie Phase 3 (venetoclax vs. pomalidomide+dex, NCT03539744) has an estimated primary completion of August 2026 and uses Pomalyst as the comparator arm.

Price Chart

Loading chart...

Executive Summary

Pomalyst (pomalidomide; Imnovid in the EU) is BMS's oral immunomodulatory drug for relapsed/refractory multiple myeloma, originally developed by Celgene and acquired by Bristol Myers Squibb, the FDA-approval catalyst is recorded 2013-02-08 in SecBot's catalyst data. It is a mature product now facing generic competition (FDA safety-labeling data, effective 2026-03-04, for generic pomalidomide from Camper/Camber Pharmaceuticals under ANDA210236) and is one small product inside a ~$65/share mega-cap trading at a hold consensus with a mean target ($64.91) roughly flat to price, so the drug itself has no scheduled binary catalyst and little ability to move BMY.

How It Works

Pomalyst is a pill in the thalidomide family of "IMiD" immunomodulatory drugs. It helps the immune system attack cancer, cuts off blood-vessel growth that feeds tumors, and directly stresses myeloma cells. It is given with the steroid dexamethasone to treat multiple myeloma that has relapsed or stopped responding after earlier therapies.

Trial Status

SecBot trial data shows no new BMS pivotal trial of pomalidomide itself: BMS/Celgene Phase 3 NCT03651128 (bb2121 vs. pomalidomide-containing standard regimens, 386 enrolled) completed 2026-04-13; Celgene Phase 2 NCT01946477 (pomalidomide+dex ± daratumumab, 186 enrolled) completed; AbbVie Phase 3 NCT03539744 (venetoclax+dex vs. pomalidomide+dex, 265 enrolled) active, est. primary completion 2026-08; a Phase 2 Kaposi sarcoma study (NCT03601806) completed 2025-04.

The Two-Sided Case

▲ Bull Case3
Approved, on-market franchise with a long track record: SecBot records an FDA approval catalyst for POMALYST on 2013-02-08 (stock +1.48% on the 1-day move around it).
Still a standard-of-care backbone in later-line myeloma: pomalidomide+dexamethasone is the comparator arm in BMS/Celgene Phase 3 NCT03651128 (386 enrolled, completed 2026-04-13) and in AbbVie's Phase 3 NCT03539744 (265 enrolled), it remains a reference therapy in the class.
The IMiD class stays strategically relevant to BMS: the next-generation successor iberdomide has a PDUFA of 2026-08-17, so BMS retains a franchise around this drug family.
▼ Bear Case4
Generic erosion is real: FDA action data shows generic pomalidomide (Camber Pharmaceuticals, ANDA210236) with safety labeling effective 2026-03-04, meaning U.S. brand exclusivity for Pomalyst is gone and revenue is being competed away.
Mature late-line niche under competitive pressure: pomalidomide is used after ≥2 prior therapies and faces newer options (CAR-T such as BMS's own bb2121, bispecifics, daratumumab-based combos) that are squeezing the same patient pool.
No catalyst and immaterial to the stock: there is no PDUFA, pivotal readout, or label decision scheduled for Pomalyst itself, and it is a minor revenue line within BMS, BMY's quant/technical profile (RSI 71.4, +48.9% over 12 months) is driven by other factors, not this drug.
Mixed tape around the ticker: SecBot's 90-day evidence checklist shows heavy 13F trimming/exits by several tracked managers and a weighted short-volume ratio of 0.52 over 60 sessions (bearish-side signals), alongside accumulation by others, no clean bullish setup from positioning.

Upcoming Catalysts

  • None scheduled for Pomalyst itself (no PDUFA/pivotal readout for this molecule in the next ~12 months).
  • BMY-level context (different molecule): iberdomide PDUFA 2026-08-17 for relapsed/refractory multiple myeloma.
  • Competitor readout using Pomalyst as comparator: AbbVie venetoclax+dex vs. pomalidomide+dex Phase 3 (NCT03539744), estimated primary completion 2026-08.
  • BMS quarterly results (10-Q filed 2026-07-30; next quarterly 10-Q) for Pomalyst/Imnovid sales trends.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov5 sec.gov